Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Preparing oxygen-containing organic compound
Patent
1997-11-04
1999-01-12
Weber, Jon P.
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Preparing oxygen-containing organic compound
435148, 514510, 560225, 568303, 568420, C12P 762, C12P 726, A01N 3700, C07C 6952, C07C 4900, C07C 4700
Patent
active
058587381
ABSTRACT:
Natural products such as certain ermophilane sesquiterpenoids and derivatives thereof are described. These compounds are useful in the inhibition of HIV integrase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. The fungal culture MF6254, Xylaria sp. (ATCC 74397) is also described and disclosed.
REFERENCES:
patent: 5759842 (1998-06-01), Dombrowski et al.
Zhao et al. "Six new eremophilane derivatives from two Ligularia species," J. Nat. Prod. (Dec. 1994) 57(12): 1626-30.
Gant et al. "Oxazoline-mediated synthesis of the Gossypium sesquiterpene lacinilene C-7 methyl ester and a structurally related HIV-1 reverse-transcriptase inhibitor," Tetrahedron Lett. (1993) 34(23): 3707-10.
Alam et al. "Substituted naphthalenones as a new structural class of HIV-1 reverse transcriptase inhibitors," Antiviral Res. (1993) 22: 131-141.
Zdero et al. "Eremophilanolides, eudesmanolides, guianolides and other constituents from Ondetia lineraris," Phytochem. (1989) 28(6):1653-60.
LaFemina et al., Antimicrobial Agents & Chemotherapy, vol. 39(2), pp. 320-324 (1995), "Inhibition of human immunodeficiency virus integrase by bis-catechols".
Cushman et al., J. Med. Chem., vol. 38 (1995), pp. 443-452, "Cosalane analogues with enhanced potencies as inhibitors of HIV-1 protease and integrase".
Mazumder et al., Biochemistry, vol. 34 (1995), pp. 15111-15122, "Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase".
Mazumder et al., J. Med. Chem., vol. 39 (1996), pp. 2472-2481, "Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease".
Mazumder et al., Molecular Pharmacology, vol. 49 (1996), pp. 621-628, "Effects of nucleotide analogues on human immunodeficiency virus type 1 integrase".
Kusumoto et al., C.A. 120(19):238888s, "A comparative study on the inhibitory effects of flavonoids and alkaloids on reverse transcriptases of different retroviruses" (1994).
Mazumder et al., AIDS Research and Human Retroviruses, vol. 11(1), pp. 115-125 (1995), "Inhibition of human immunodeficiency virus type 1 integrase by a hydrophobic cation . . . ".
Mazumder et al., Proc. Nat'l Acad. Sci. USA, vol. 91, pp. 5771-5775 (1994), "Inhibition of human immunodeficiency virus type 1 integrase by 3'-azido-3'-deoxythymidylate".
Carteau et al., Archives of Biochemistry & Biophysics, vol. 305(2), pp. 606-610 (1993), "Inhibitory effect of the polyanionic drug suramin on the in vitro HIV DNA integration reaction".
Fesen et al., Proc. Nat'l Acad. Sci. USA, vol. 90 (1993), pp. 2399-2403, "Inhibitors of human immunodeficiency virus integrase".
Farnet et al., Proc. Nat'l Acad. Sci. USA, vol. 93 (1996), pp. 9742-9747, "Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules".
Lutzke et al., Proc. Nat'l Acad. Sci. USA, vol. 92 (1995), pp. 11456-11460, "Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library".
Ojwang et al., Antimicrobial Agents & Chemotherapy, vol. 39(11), pp. 2426-2435 (1995), "T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor . . . ".
Eich et al., J. Med. Chem., vol. 39 (1996), pp. 86-95, "(-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus type-1 integrase".
Robinson, Jr., et al., Proc. Nat'l Acad. Sci. USA, vol. 93 (1996), pp. 6326-6331, "Inhibitors of HIV-1 replication that inhibit HIV integrase".
PRNewswire, Sep. 17, 1996, "Aronex reports results for lead anti-HIV integrase inhibitor compound".
Neamati et al., "Design and discovery of HIV-1 integrase inhibitors", DDT 2(11) (1997), pp. 487-498.
Hazuda et al., Nucleic Acids Research, vol. 22 (6), pp. 1121-1122 (1994), "A novel assay for the DNA strand-transfer reaction of HIV-1 integrase".
Burke et al., J. Med. Chem., vol. 38 (1995), pp. 4171-4178, "Hydroxylated aromatic inhibitors of HIV-1 integrase".
Hazuda et al., J. of Virology, vol. 71(1), pp. 807-811 (1997), "Equivalent inhibition of half-site and full-site retroviral strand transfer reactions by structurally diverse compounds".
Fesen et al., Biochemical Pharma., vol. 48(3), pp. 595-608 (1994), "Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (cape) and related compounds".
Lingham Russell B.
Polishook Jon David
Shafiee Ali
Silverman Keith C.
Singh Sheo Bux
Fitch Catherine D.
Hanley Susan
Merck & Co. , Inc.
Weber Jon P.
Winokur Melvin
LandOfFree
Ermophilane sesquiterpenoids as HIV intergrase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ermophilane sesquiterpenoids as HIV intergrase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ermophilane sesquiterpenoids as HIV intergrase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1514413